

Pharnext to Present at 4th International Neurotech Investing and Partnering Conference

Paris, France, 5:45pm, September 28, 2017 (CEST) – Pharnext SA (FR00111911287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the 4th International Neurotech Investing and Partnering Conference.

The presentation will take place as follows:

- **Date:** Wednesday, October 4th, 2017
- **Time:** 4:00pm CEST
- **Venue:** Wyss Center in Geneva, Switzerland

If you are interested in meeting the Pharnext management team during this event, please send an email to Anne Hennecke at anne.hennecke@mc-services.eu.

About Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer's disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR00111911287). For more information, visit www.pharnext.com

CONTACTS:

Pharnext

Xavier Paoli

Chief Commercial Officer

contact@pharnext.com

+33 (0)1 41 09 22 30

Investor Relations (Europe)

MC Services AG

Anne Hennecke

anne.hennecke@mc-services.eu

+49 211 529252 22

Investor Relations (U.S.)

Stern Investor Relations, Inc.

Matthew Shinseki

matthew@sternir.com

+1 212 362 1200

Financial Communication (France)

Actifin

Stéphane Ruiz

sruiz@actifin.fr

+33 (0)1 56 88 11 15

Media Relations (Europe)

ALIZE RP

Caroline Carmagnol

Margaux Pronost

pharnext@alizerp.com

+33 (0)1 44 54 36 64

Media Relations (U.S.)

RooneyPartners

Marion Janic

mjanic@rooneyco.com

+1 212 223 4017